Tto be spread over 2,000 sq metres, it will be a Bio Safety Level 2 and 3 facility that will cater to the viral vaccines in the company’s development pipeline, including its potential Covid-19 vaccine candidate as well as those for dengue, zika and varicella, IIL said on Wednesday.
In addition to the viral antigen facility, the ground breaking for which was done on Wednesday, IIL also inaugurated a Rs 75 crore sterile filling facility at Karkapatla that was commissioned last year.
IIL said the new filling facility enhances its production capacity by over 35%, helping it ramp up supply of lifesaving vaccines, such as anti-rabies vaccine Abhayrab, to key markets. The expansion will increase IIL’s headcount from around 1300 to 1,500.
Terming the investment as strategic, IIL managing director K Anand Kumar said the total investment of over Rs 150 crore is part of IIL’s vision to increase production capacities to ensure a reliable and affordable supply of high-quality vaccines to larger communities.
IIL currently has four manufacturing facilities, including three in India and one in New Zealand. It has capacities for human vaccines and animal health formulations at Karkapatla as well as human biologicals and animal vaccines units at Gachibowli in Telangana. It also has an anti-rabies vaccine production unit at Ooty in Tamil Nadu and a new bovine serum facility at Dargaville in New Zealand.